中文Vientiane, Laos - May 11, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative treatments for cancer, announced today that Eltrombopag has been approved by the Lao Ministry of Health.
Approved drugs are:
Eltrombopag: sold under the brand name ELTROMDX, for the treatment of thrombocytopenia in children one year of age and older with idiopathic thrombocytopenia who have had an inadequate response to corticosteroids, immunoglobulins, or splenectomy.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.